Dr. Bohen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
875 Blake Wilbur Dr
Palo Alto, CA 94304Phone+1 650-723-7621
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1999 - 2001
University of California San Francisco School of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 1999 - 2025
Publications & Presentations
PubMed
- 1171 citationsLebrikizumab Treatment in Adults with AsthmaJonathan Corren, Robert F. Lemanske, Nicola A. Hanania, Phillip E. Korenblat, Merdad V. Parsey
The New England Journal of Medicine. 2011-09-21 - 255 citationsMutant conformation of p53 translated in vitro or in vivo requires functional HSP90Mikhail V. Blagosklonny, Jeffrey A. Toretsky, Sean P. Bohen, Len Neckers
Proceedings of the National Academy of Sciences of the United States of America. 1996-08-06 - 136 citationsDose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroidsMichael Noonan, Phillip E. Korenblat, Sofia Mosesova, Heleen Scheerens, Joseph R. Arron
The Journal of Allergy and Clinical Immunology. 2013-09-01
Press Mentions
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 StudyMay 11th, 2023- Olema Plans Pivotal Trial for Two-Prong Breast Cancer TreatmentJanuary 5th, 2023
- HER2 Breast Most Cancers Therapeutic, OP-1250, Receives Section 2 Dose SuggestionDecember 10th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
